XLO | Xilio Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.9750 - 1.1600
52 Week Range	0.5000 - 1.9300
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	648,814
Average Volume	501,964
Shares Outstanding	43,958,073
Market Cap	49,233,042
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-10-22

Valuation
Profitability
Growth
Health
P/E Ratio	-0.72
Forward P/E Ratio	N/A
EPS	-1.55
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	73
Country	USA
Website	XLO

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

XLO's peers: EWTX, IKNA, JSPR, LVTX, RAPT, SVRA, TARA, TNGX, TYRA, URGN, VERA, CNTB, MLYS, DSGN, ELYM, ANEB, ANTX, AVTE, ADAG, MOLN, MNOV, CSBR, CYT, SNTI, GRI

*Chart delayed

Analyzing fundamentals for XLO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see XLO Fundamentals page.

Watching at XLO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on XLO Technicals page.